LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for treating type 2 diabetes mellitus in adults. Whilst the medication effectively controls blood sugar levels, questions have emerged regarding ozempic and bone loss, particularly in relation to the weight reduction that often accompanies treatment. Current evidence does not demonstrate a direct effect of Ozempic on bone tissue, and neither NICE nor the MHRA recommend routine bone monitoring for patients taking GLP-1 receptor agonists. However, understanding the relationship between rapid weight loss and bone health remains important for patient safety and informed clinical decision-making.
Quick Answer: Current UK evidence does not show that Ozempic directly causes bone loss or increases fracture risk in patients with type 2 diabetes.
Ozempic (semaglutide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus in adults. It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the action of a naturally occurring hormone that regulates blood sugar levels and appetite.
The medication is administered as a once-weekly subcutaneous injection and works through several mechanisms. Primarily, it stimulates insulin secretion from the pancreas when blood glucose levels are elevated, whilst simultaneously suppressing the release of glucagon, a hormone that raises blood sugar. Ozempic also slows gastric emptying, meaning food moves more slowly from the stomach into the small intestine, which helps to reduce post-meal blood sugar spikes and promotes a feeling of fullness.
A consequence of Ozempic treatment is weight loss, which occurs as a result of reduced appetite and caloric intake. Whilst this can be beneficial for individuals with type 2 diabetes who are overweight or obese, rapid or substantial weight loss has raised questions about potential effects on bone health. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ozempic specifically for glycaemic control in type 2 diabetes, and it should only be prescribed by healthcare professionals following appropriate clinical assessment.
It is important to note that Ozempic is not licensed in the UK for weight management in people without diabetes, although a higher-dose formulation of semaglutide (Wegovy) has been approved for this specific indication. Patients should always use Ozempic under medical supervision and discuss any concerns about side effects, including those related to bone health, with their GP or diabetes specialist.
Concerns about bone health in patients taking Ozempic primarily relate to the rapid weight loss that can occur during treatment, rather than a direct pharmacological effect of the medication on bone tissue. Current NICE, MHRA and European Medicines Agency (EMA) guidance does not recommend bone monitoring specifically due to GLP-1 receptor agonist use, and available evidence has not shown increased fracture risk with these medications. However, understanding the relationship between weight loss and bone density is important for patient safety.
Rapid weight loss from any cause can potentially affect bone mineral density (BMD). When the body loses weight quickly, particularly if accompanied by inadequate nutritional intake, there may be insufficient calcium, vitamin D, and protein to maintain optimal bone health. Additionally, reduced mechanical loading on bones due to lower body weight can decrease the stimulus for bone formation. Research suggests that unintentional weight loss of ≥5-10% over 3-6 months may be associated with modest reductions in BMD, though the clinical significance of these changes varies between individuals.
Several patient-specific risk factors may increase vulnerability to bone health concerns during weight loss treatment:
Age: Postmenopausal women and older adults are at higher baseline risk of osteoporosis
Pre-existing low bone density or previous fragility fractures
Inadequate dietary calcium and vitamin D intake
Sedentary lifestyle with limited weight-bearing exercise
Certain medications that affect bone metabolism (e.g., corticosteroids, pioglitazone, certain anticonvulsants)
Medical conditions such as coeliac disease, inflammatory bowel disease, or hyperthyroidism
Smoking and excessive alcohol consumption
Patients with multiple risk factors should discuss bone health monitoring with their healthcare team before starting Ozempic. Current UK guidance (NICE NG226 and NOGG 2024) recommends fracture risk assessment using tools such as FRAX® or QFracture® for at-risk populations, with subsequent DXA scanning if indicated by risk thresholds.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
Maintaining bone health whilst taking Ozempic involves a multifaceted approach focusing on nutrition, physical activity, and appropriate medical monitoring. These strategies are consistent with general bone health recommendations from the Royal Osteoporosis Society and NHS guidance.
Nutritional considerations are paramount during weight loss treatment. Patients should aim to:
Ensure adequate calcium intake (700mg daily for adults, as recommended by the NHS) through dairy products, fortified plant-based alternatives, leafy green vegetables, and tinned fish with bones
Maintain sufficient vitamin D levels (10 micrograms daily supplement recommended for most UK adults during autumn and winter months, and year-round for those at higher risk or with limited sun exposure)
Consume adequate protein (at least 0.75g per kilogram of body weight daily for most adults; consider 1.0-1.2g/kg/day for older adults or during weight loss) to support muscle and bone health
Avoid very low-calorie diets unless under specialist supervision
Consider referral to a registered dietitian for personalised nutritional guidance
Weight-bearing and resistance exercise provides essential mechanical stimulus for bone formation. The UK Chief Medical Officers recommend adults engage in:
At least 150 minutes of moderate-intensity activity weekly
Weight-bearing exercises such as walking, jogging, dancing, or tennis
Resistance training at least twice weekly to maintain muscle mass and bone strength
Balance exercises to reduce fall risk, particularly important for older adults
Patients experiencing significant weight loss should aim for a gradual, sustainable rate of 0.5–1kg per week where possible. Whilst Ozempic may produce more rapid initial weight loss, working with healthcare professionals to optimise the dose and maintain adequate nutrition can help mitigate potential bone health concerns.
Additional lifestyle measures include smoking cessation and limiting alcohol consumption within UK low-risk drinking guidelines (no more than 14 units per week).
Medical monitoring may be appropriate for high-risk individuals. Your GP may recommend:
Fracture risk assessment using FRAX or QFracture tools, with DXA scanning if indicated by NOGG thresholds
Vitamin D testing if deficiency is clinically suspected
Consideration of bone-protective medications if indicated by risk assessment
Patients taking Ozempic should maintain open communication with their healthcare team regarding any concerns about bone health. Whilst routine bone density monitoring is not currently recommended for all patients on GLP-1 receptor agonists, certain circumstances warrant medical review.
Contact your GP or diabetes specialist if you experience:
Unexplained bone pain or persistent musculoskeletal discomfort
Fractures from minor trauma (fragility fractures), which may indicate underlying bone weakness
Significant unintentional weight loss of ≥5-10% over 3-6 months
Difficulty maintaining adequate nutrition due to gastrointestinal side effects
New or worsening symptoms suggesting calcium or vitamin D deficiency (muscle cramps, weakness, fatigue)
Proactive discussion is particularly important if you:
Are postmenopausal or over 65 years of age
Have a personal or family history of osteoporosis or fragility fractures
Take medications that affect bone health (corticosteroids, aromatase inhibitors, pioglitazone)
Have medical conditions associated with bone loss
Experience rapid weight loss that concerns you
Have limited mobility or are unable to perform weight-bearing exercise
Your GP can assess your individual fracture risk and determine whether investigations such as DXA scanning are appropriate. According to current UK guidance (NICE NG226 and NOGG 2024), bone density assessment should be considered for individuals with clinical risk factors for fragility fracture based on FRAX or QFracture thresholds. If bone density is found to be low, treatment options including bisphosphonates, denosumab, or other bone-protective therapies may be discussed.
It is important to emphasise that the benefits of Ozempic for glycaemic control in type 2 diabetes are well-established. Clinical trials (SUSTAIN-6) have also shown cardiovascular benefits in people with type 2 diabetes and high cardiovascular risk. Decisions about continuing or modifying treatment should always be made collaboratively with your healthcare team, weighing the proven benefits against any potential risks. Never stop taking prescribed medication without medical advice, as this could lead to deterioration in diabetes control and associated complications.
If you suspect you have experienced a side effect from Ozempic, you can report this through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).
Current evidence does not show that Ozempic has a direct pharmacological effect on bone tissue or increases fracture risk. Bone health concerns relate primarily to rapid weight loss rather than the medication itself, and UK regulatory guidance does not recommend routine bone monitoring for GLP-1 receptor agonist use.
Postmenopausal women, older adults, individuals with pre-existing low bone density or previous fragility fractures, and those taking bone-affecting medications (such as corticosteroids) should discuss bone health monitoring with their GP before starting Ozempic.
Maintain adequate calcium intake (700mg daily), take vitamin D supplements (10 micrograms daily), consume sufficient protein, engage in regular weight-bearing and resistance exercise, and aim for gradual weight loss of 0.5–1kg weekly where possible.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
